After an internal audit of its accounting practices discovered problems that will force the company to restate five years' worth of financial records, MiMedx Group(NASDAQ:MDXG) shareholders were dealt more bad news today when Blue Cross/Blue Shield parent Health Care Service Corp. announced it will no longer cover the company's injectable amniotic-tissue products.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,